(2026). Healthcare resource utilization and readmission outcomes in patients treated with ceftolozane/tazobactam: Real-world insights from the multinational SPECTRA study. JAC-Antimicrobial Resistance.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Healthcare Resource Utilization and Readmission Outcomes in Patients Treated with Ceftolozane/tazobactam: Real-world Insights from the Multinational SPECTRA Study."
JAC-Antimicrobial Resistance 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Healthcare Resource Utilization and Readmission Outcomes in Patients Treated with Ceftolozane/tazobactam: Real-world Insights from the Multinational SPECTRA Study."
JAC-Antimicrobial Resistance, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.